<DOC>
	<DOCNO>NCT01304810</DOCNO>
	<brief_summary>The purpose study obtain two year follow data subject receive six vaccination NicVAX prior phase III study . No treatment administer . Anti-nicotine antibody level safety data collect .</brief_summary>
	<brief_title>A Follow-up Study Assess Long-term Immunogenicity Safety NicVAX/Placebo Aid Smoking Cessation</brief_title>
	<detailed_description>This study follow subject participate NicVAX phase III study second year . These predecessor study , Nabi-4514 ( NCT # 00836199 ) Nabi-4515 ( NCT # 01102114 ) evaluate efficacy safety 6 vaccination NicVAX placebo aid smoking cessation . The two phase III study one year duration , subject complete study eligible enroll Nabi-4522 . As phase III study ongoing , subject assignment NicVAX placebo remain mask . No intervention administer Nabi-4522 . Subjects follow immunogenicity ( anti-nicotine antibody level ) safety .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects agree sign consent participate followup study . Subjects randomize complete month 12 Nabi4514 Nabi4515 study . Subjects receive total 6 injection Nabi4514 Nabi4515 . Anticipated inability follow study protocol throughout study period . Known history condition factor judge investigator preclude participation study might hinder compliance failure sign inform consent . Subjects intend receive , receive Investigational New Drug/Device study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>NicVAX</keyword>
	<keyword>Smoking cessation</keyword>
</DOC>